KGISL Completes Acquisition of AETINS, Expands Expertise in the Insurance Space

Singapore / Malaysia, Jun 29, 2021 – (ACN Newswire) – KG Information Systems Private Limited (KGISL), a global IT services, consulting, and business solution provider, today announced the acquisition of AETINS Sdn. Bhd. through its wholly-owned subsidiary in Malaysia, KG Information Systems Sdn. Bhd. The acquisition is a part of KGISL's growth strategy in the InsurTech space.

Prassadh Shanmugam, Director and Chief Executive Officer, KGISL

AETINS brings aboard an exceptional range of insurance solutions for Life, General and Takaful bundled with an unmatched domain expertise. AETINS' Core Insurance Product and Solutions are well known in the market and are market-leading. The company serves a vast clientele of insurance firms in the Asia Pacific, Middle East, and North Africa. The people, products, and solutions from AETINS would be leveraged in expanding KGISL's footprint in the InsurTech space.

KGISL has market presence in the Malaysia InsurTech space since 2006 and has grown as a market leader with its Point of Sale (PoS) and Claims Management Solution for the Non-Life Insurance segment. The acquisition of AETINS will now bring in Core Insurance Product and Insurance Solution Framework (ISF) into KGISL's product offerings and opens doors to enter the wider Asia Pacific, Middle East, and Africa markets covering the Life, Non- Life and Takaful Insurance segments.

Mr. Prassadh Shanmugam, Director and Chief Executive Officer, KGISL commenting on the acquisition said, "I am super excited about this acquisition. AETINS' Core Insurance products, Takaful offerings and good presence in the Middle East market are the missing pieces in KGISL's Insurance offerings. It would have taken years for us to build this capability, so the acquisition is a perfect fit for KGISL. The employees of AETINS share the same integrity, culture and value systems of KGISL, so the integration will also be smooth and quick."

Commenting on the acquisition, Dr Ashok Bakthavathsalam, Managing Director, KGISL said, "The acquisition brings together two leading InsurTech players in pursuit of a common mission, centred on providing the best value for customers, organisation and employees. With able leadership and a go-getter team, KGISL has been on a fast growth trajectory, clocking a five-fold growth in the last four years. This acquisition adds momentum, and I am confident that our growth will be even faster in the next 3 years."

About KGISL – www.KGISL.com/gss

KG Information Systems Private Limited (KGISL) is a global IT Services, Consulting and Business Solutions provider in the BFSI space. KGISL offers Software Products, Solutions and Services in Intelligent Automation, ERP (SAP), CRM, Business Intelligence and Analytics, Quality Engineering, IT Infrastructure Management and Application Development. KGISL has offices in India, US, Malaysia (201301013805), Singapore, Australia and Thailand.

KGISL is part of the $750 million business conglomerate KG Group with interest in Textiles, Engineering, Healthcare, Education, Real Estate, Entertainment, Software and Business Support Services. The Group employs over 25000 people and is known for its philanthropic services to the community for over 8 decades.

About AETINS (199801000924) – www.aetins.com

AETINS, established in 1998, is a single end-to-end Insurance and Takaful Solution provider that covers all lines of business: Individual Life, Group Life, Investment Linked and General. It spans across functions like illustration, quotation, new business, policy servicing, claims, agency management, commission and benefits, accounting and services. Our business is to help Insurance and Takaful Companies to strategize and operate by leveraging on Information Technology, a key enabler to achieve transformational growth through Operational Excellence and Innovation. See www.aetins.com.

For further information, please contact:

KGISL: Sampathkumar S | sampathkumar.s@KGISL.com | +91 9940069884

Adfactors PR (India):
Bhargav TS | bhargav.ts@adfactorspr.com | 9884883350
Shamitha Hegde | shamitha.hegde@adfactorspr.com | 9003107361

Adfactors PR (Singapore):
Namrata Sharma | namrata.sharma@adfactorspr.com | +65 8138 3034

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Kindstar Globalgene Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Jun 28, 2021 – (ACN Newswire) – A leading player in China's independent esoteric clinical testing service provider – Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, the "Group", stock code: 9960.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").

Kindstar Globalgene plans to offer 226,405,000 Shares (subject to the Over-allotment Option), of which 203,764,500 Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing 90% of the initial offer shares; the remaining 22,640,500 Shares will be Hong Kong Offer Shares (subject to reallocation), representing 10% of the initial offer shares. Offer Price is between HK$8.60 and HK$9.78 per Share. Kindstar Globalgene will open for Hong Kong Public Offering in Hong Kong at 9 a.m., June 29, 2021 (Tuesday), and close at 12:00 noon, July 7, 2021 (Wednesday). Dealings in shares of Kindstar Globalgene on the Main Board of the Hong Kong Stock Exchange is expected to commence on July 16, 2021 (Friday). The shares will be traded in board lot of 500 Shares each. The Company's stock code is 9960.HK.

Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited and Credit Suisse (Hong Kong) Limited are the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.

Dr. Huang Shiang, Executive Director, Chairman, Chief Executive Officer and Chief Medical Officer of Kindstar Globalgene Technology, Inc., said, "Our mission is to offer patients and physicians worldwide broad and high- quality specialty testing services and promote the application of precision medicine. In the furture, we will strengthen our leading position in Hematology Esoteric Clinical Testing in China. Also, we will replicate our success in hematology esoteric testing to expedite growth in other specialty areas. What's more, we will deepen our strategic collaboration with leading industry participants to facilitate the growth of our business and enhance the overall development of China's esoteric testing industry. In addition, we aim to enhance our leadership on a global scale by deepening our cooperation with trustworthy local partners.

About Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc. is the first and leading independent esoteric clinical testing service provider in China. Kindstar Globalgene has the largest esoteric testing portfolio among all the independent esoteric testing providers in China, with over 3,500 testing items in our service menu, which includes over 2,300 testing items for hematology. There are over 1,100 testing items were developed fully internally, and approximately 2,400 testing items were developed by or in-licensed from third parties. Kindstar Globalgene provide full-spectrum testing services in various specialty areas, including hematology, genetic diseases and rare diseases, infectious diseases, oncology, neurology and maternity-related diseases.

Issued by Porda Havas International Finance Communications Group for and on behalf of Kindstar Globalgene Technology, Inc.. For further information, please contact:

Porda Havas International Finance Communications Group
Ms. Kelly Fung +852 3150 6763 kelly.fung@pordahavas.com
Ms. Ivy Lu +852 3150 6788 Ivy.lu@pordahavas.com
Ms. Louise Liu +8621 3397 8796 Louise.liu@pordahavas.com
Ms. Mona chen +8521 3397 8796 Mona.chen@pordahavas.com

Important Disclaimers:
1. This press release is for information purposes only and does not constitute or include any recommendation or invitation or offer (nor is calculated to invite such a recommendation, offer or invitation) by any person for acquisition, purchase or subscription of the securities of the Company nor does it intend to act as a recommendation of the sale of securities or any invitation, solicitation or offer for acquisition, purchase or subscription of securities in any jurisdiction. This press release should accordingly not amount an advertisement or invitation within the meaning of section 103(1) of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) or a prospectus or an extract from or abridged version of a prospectus (including within the meaning of sections 2 and 38B, respectively of the Companies (Winding Up and Miscellaneous Provisions) Ordinance). This press release has not been reviewed or approved by The Stock Exchange of Hong Kong Limited or the Securities and Futures Commission of Hong Kong. Investors should read the prospectus of the Company for detailed information about the Company and the proposed offering before deciding whether or not to purchase any securities of the Company. An application to subscribe for the shares referred to in this press release by any persons shall be made solely based on the prospectus and the application forms to be issued by the Company on June 29, 2021.

2. No application for the shares of the Company should be made by any person nor would such application be accepted without the completion of a formal application form or other application procedure that is issued with or in respect of the prospectus.

3. The directors of the Company collectively and individually accept full responsibility for the accuracy of the information contained in this press release and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts the omission of which would make any statement herein misleading.

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Kindstar Globalgene Proposed Listing on the Main Board of the Hong Kong Stock Exchange

China Biotech Services (8037.HK): Confident shareholders are taking long on their books in anticipation of promising results to be generated from the double engines of growth on cell therapy and precision diagnostic businesses

HONG KONG, Jun 28, 2021 – (ACN Newswire) – 2021-6-23 / Gelonghui – The Company's self-developed cell therapy product was approved by NMPA to enter into phase I clinical trial as a class I new drug

Source: official website of NMPA

With the recent approval of the first CAR-T cell therapy product for marketing in China, a brand-new era of immune cell therapy has just begun.

According to the announcement of National Medical Products Administration of China (NMPA), Axicabtagene Ciloleucel injection (code name: FKC876), a CAR-T cell therapy product of Fosun Kite, was officially approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (including diffuse large B-cell lymphoma (DLBCL) non-specific type, primary mediastinal B-cell lymphoma (PMBCL), high-grade B-cell lymphoma and DLBCL transformed from follicular lymphoma) after second-line or higher systemic therapy.

China Biotech Services took its first show in the field of CAR-T cell R&D through its acquisition of Shanghai Longyao Biotech in July 2018.

By now, Shanghai Longyao Biotech has built a first-class scientific and R&D transformation team and has pooled up more than 10 products in pipeline, of which four have obtained international technology patents and the other six are pending for completion of applications. Other than those popular target markers, the Company has developed certain proprietarily structured CAR-T. Based on the number of proprietary patents on hands, the distinctive progress made in filing for clinical trials and those highly regarded articles published in top international medical journals (e.g. Science Translation Medicine), Shanghai Longyao Biotech has proved itself to be amongst the first-tier players in the global CAR-T field.

With respect to the latest progress of those pipelines, CD20-CART-OX40 product has received the approval to kick off the clinical trial as a Class I Investigational New Drug (IND) on January 20, 2021.

At almost the same time, Professor Yang Xuanming, the chief scientist of Shanghai Longyao Biotech, published his article on CD20-CART-OX40 in Science Translational Medicine on January 27, 2021, EST.

The article specifically highlighted the findings of such cell product's potential efficacy against solid tumors. The clinical data will support the Company's subsequent research on making use of the product to tackle solid tumors.

CLDN18.2-CART-OX40, the Company's second CAR-T product for treatment of solid tumors, has now passed ethical and academic reviews for pancreatic and gastric cancers at the Affiliated Hospital of Xuzhou Medical University, Jiangsu Province. The Company has started investigator-initiated trial on the product and is in the process of patient enrolment. The Company has prepared to start investigator-initiated clinical trial of the product at Ruijin Hospital, Shanghai.

In addition, the generic UCART- CD19, which has passed academic and ethical review at Huaian People's Hospital, Jiangsu Province, has started an investigator-initiated trial which is in the process of patient enrolment.
Once the cell therapy products have got through the respective stages of clinical trials one by one, it is expected that Shanghai Longyao Biotech can become one of the leaders in the development of cell therapies.

II. A comprehensive scope of diagnostic products that can secure sustainable business growth

Over the past one year, the outbreak of COVID-19 pandemic has brought rapid business growth for companies in medical diagnostic industry. Yet, there are concerns in the market that once the outbreak is under control, the performance of these third-party medical diagnostic companies will gradually fade out. How to maintain sustainable business growth is a problem being faced by the whole industry. China Biotech Services' revenue continued to grow by 1,113% in the first quarter of this year on a year-on-year basis, after recording a remarkable growth in last year. This is mainly attributable to the Company's comprehensive scope of medical diagnostic products, the ownership of three well-positioned medical laboratories, as well as the synergistic growth of businesses in three health check-up centres located in strategic regions of Hong Kong. The key highlights are listed out as follows:

1. Sunrise Diagnostic Centre is focusing on the provision of nucleic acid testing for COVID-19. The overall community demand for testing business has remained strong due to the continuous mutation of the virus and the ongoing spread of virus. Being a member company of China Biotech Services, Sunrise Diagnostic Centre is one of the largest nucleic acid testing providers in Hong Kong. It has once served as the main contractor of the universal testing program for COVID-19 in Hong Kong lasting from July to September 2020. During the period, 1.68 million people had taken the tests within 15 days with 44 positive cases identified. The program had effectively cut off 10 virus transmission chains and had proved to be crucial for the Hong Kong government to suppress the third wave of the outbreak. As well, Sunrise Diagnostic Centre is the appointed service provider to perform quarantine testing for arrival passengers at the Hong Kong International Airport since December 2020. Since then, the Sunrise team has successfully shortened the turnaround time of the test to less than two hours. This has brought significant improvement of service to those inbound passengers and has assisted the government to enhance the efficiency of passenger clearance at the Hong Kong International Airport.

2. Set up in 1968 with a history of 53 years, PHC Medical Diagnostic Laboratory is a third-party medical testing centres well-established in Hong Kong with good brand recognition. PHC offers a wide range of tests to clients covering almost all medical diagnostic items related to pathology, blood, biochemistry, immunology, radiology and others. Its clients come from many leading insurance companies and private clinics in Hong Kong. The PHC Medical Diagnostic Laboratory has also launched its Abbott Serum Antibody Testing Platform recently to provide neutralizing antibody testing services for vaccinated clients.

3. Serum antibody testing business is set to become a new growth driver
A. According to the latest quarantine arrangement for the control and prevention of COVID-19 that will become effective from 1 July 2021, Hong Kong residents who have taken serum antibody tests at their own expense in any recognised local laboratory before leaving Hong Kong with results showing that their antibody levels in sera are acceptable and return to Hong Kong within the next three months, the quarantine period can be shortened. For non-Hong Kong residents arriving in Hong Kong on or after 1 July 2021, the Hong Kong government will arrange for user-paid serum testing services at the airport. With satisfactory results found in both the serum antibody and nucleic acid tests at the airport, those non-Hong Kong residents who have been vaccinated will only need to be quarantined for seven days. This newly adopted policy is effectively reopening the boundary for travellers to go in and out of Hong Kong and as a result will boost the demand for serum antibody testing.

B. In addition, relevant statistics show that since the official launch of the COVID-19 vaccination program on 26 February 2021 and up to 20 June 2021, a total of about 3.28 million Hong Kong residents have been vaccinated. The market for post-vaccination antibody testing will also create a new opportunity for voluntary antibody testing.
C. Once the pandemic is brought under control, Hong Kong will surely move to reopen the boundary and to encourage more international travels for promotion of economic growth. While the overseas development of pandemic is largely uncertain even by now, the COVID-19 nucleic acid testing and antibody testing are expected to stay essential in the market for a longer time. The continuous mutation of the virus and the development of the pandemic are going to normalize the nucleic acid and antibody testing businesses and will bring sustainable growth to the Company.

Conclusions:
The Company is riding on double engines of growth in both medical diagnostic and cell therapy businesses. The medical diagnostic business has formed the bedrock of the Company's growth by providing stable income and cash flow. The medical diagnostic part is set to growth with the inclusion of more innovative tests apart from the COVID-19 related testing. The income stream from the medical diagnostic business is sufficient to support the capital requirements in the R&D phase of the cell therapy products. Once the development of cell therapy products gets into the harvest period, the Company will experience a new phase of rapid growth. Based on a comparison of key performance data with peer group companies in either the medical diagnostic sector or the cell therapy development sector, the outlook of the Company is rather promising as a value pick.

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avance Clinical Appoints Asia Biotech Specialist to Support APAC Growth

ADELAIDE, AUS, Jun 28, 2021 – (ACN Newswire) – Avance Clinical, the leading Australian CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient, announced the appointment of Andy Hu as Business Development Manager APAC, to support increasing biotech clinical trial demand from the region.

Andy Hu

Formerly with Informa Pharma Intelligence, the international biopharma data company, Andy will head up the APAC business development program for Avance Clinical.

Andy says the main drivers for Asian biotechs looking to Australia are speed, data quality and access to international regulatory authorities.

"They select Avance Clinical in Australia because its CRO data is accepted by the FDA, and it gives them a rapid pathway for international licensing, investment and ultimately drug approvals," he said.

"I wanted to work with Avance Clinical because it's a mid-sized CRO that offers deep therapeutic experience, expedited timelines, and exceptional support to APAC biotech clients."

Avance Clinical has grown significantly over the past two years with an increasing number of clients coming from APAC to conduct their trials in Australia.

Chief Strategy Officer Ben Edwards said the appointment of Andy Hu will further support growth and strengthen relationships with clients in the region.

"Andy is multilingual, being fluent in English, Mandarin and Korean, and has completed both a Bachelor of Korean Language and Culture as well as a Master of Translation and Interpreting. He will be responsible for developing business across the APAC region to better serve our clients operating in the region," he said.

The Avance Clinical team is attending BIO Digital 2021 virtually and is available on the BIO One-on-One Partnering(TM) platform to discuss the benefits of conducting trials in Australia.

Avance Clinical has recently won the BDO Excellence in Business Award 2021 for rapid managed growth and attracting and nurturing experienced staff in a competitive global environment.

The mid-sized CRO has a reputation for going beyond the industry time and support for Sponsors, and for providing staff the training and resources needed to deliver excellence in clinical research management.

About Avance Clinical

Avance Clinical is the largest specialist Australian CRO delivering quality clinical trials in Australia and New Zealand for international biotechs. Avance Clinical has been delivering CRO services in the region for the past 24 years. Our clients are international biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach. As a company we have focussed on state-of-the-art technology and systems across all functional areas to provide our clients with the most effective processes. Medidata, Oracle, and Medrio are just some of our technology partners. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of candidates who demonstrate passion and expertise in their chosen field. Visit http://www.avancecro.com for more information.

Recent Awards:
Excellence in Business Award 2021
Frost & Sullivan Asia-Pacific CRO Market Leadership Award 2020

Media Contact:
media@avancecro.com

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avantor Named Best Company in Bioprocessing Excellence for Single-use Solutions and Best Bioprocessing Supplier for Upstream Processing at Biologics Manufacturing Korea 2021

Seoul, Korea, June 25, 2021 – (ACN Newswire) – Avantor, a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies and applied materials industries, was named best company in bioprocessing excellence for single-use solutions and best bioprocessing supplier for upstream processing at Biologics Manufacturing Korea (BMK) 2021.

Sang Kyu Lee, Representative Director – Avantor Korea/Japan(centre), Jin Young Lee, Biopharma Business Manager – Avantor Korea/Japan(left), James Hwang, Innovation Center Field Application & Education Manager – Avantor Korea/Japan(right), after receiving the Awards for Best Company in Single-use Solutions and Upstream Processing at BMK 2021.

This is the second consecutive year Avantor has been selected as the best company in the single-use category at BMK. As the development and supply of biopharmaceuticals, including COVID-19 vaccines and therapeutics, become more important than ever, Avantor has been actively supporting the discovery to delivery of biopharmaceutical therapies to both domestic and foreign pharmaceutical companies. A key piece of this contribution is supplying differentiated upstream solutions such as high-purity materials.

Avantor also has been recognized for its ongoing efforts to develop single-use solutions, which are emerging as the preferred option to improving biopharmaceutical manufacturing processes. Avantor is responding to rapidly increasing needs for treatments and therapies by providing customized solutions to biopharma companies. Avantor closely analyzes manufacturing processes to support customers with increased yield and reduced resources when developing new therapeutics.

SK Lee, Sales Director of Avantor Korea & Japan, said, “We are extremely proud to be recognized by BMK for our leadership in bioprocessing development by providing solutions to biopharmaceutical manufacturers. Working closely with our customers, we play a critical role in enabling breakthroughs in life-changing biologics.”

Narayana Rao Rapolu, Vice President, Biopharma Asia Middle East & Africa for Avantor said, “Avantor’s continued investment in single-use solutions, including our recent acquisition of RIM Bio, with manufacturing capabilities in China, go a long way to demonstrate our commitment to delivering bioprocessing excellence. Our process development and optimization capabilities carried out by our dedicated expert researchers at our Korea Innovation Center is helping customers deliver on cost and time efficiencies.”

For more information on Avantor’s single-use solution for biopharmaceutical manufacturing, visit https://youtu.be/mfjZEfO_RVM.

About Avantor

Avantor^®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For information, visit and find us on LinkedIn, Twitter and Facebook.

About Biologics Manufacturing Korea Excellence Award 2021

The Biologics Manufacturing Korea Excellence Award seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence with enhanced speed, reduced cost, and superior quality. 2021 marks the tenth year of ABEA. The BMK Awards is part of the Asia-Pacific Bioprocessing Excellence Awards (ABEA) which seeks to recognize organizations within Korea who have engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality and safety in biological products manufacturing.

AMEA Media Contact
Christina Koh
Director – Communications, AMEA
Avantor
Phone: +65 9170 0169
Email: Christina.Koh@avantorsciences.com

MainettiCare Becomes Official Face Mask Supplier of Hong Kong, China Delegation to Tokyo 2020 Olympic Games

HONG KONG, Jun 24, 2021 – (ACN Newswire) – Mainetti Group ("Mainetti" or the "Company"), the leading global retail solutions provider, is pleased to announce that MainettiCare – the Company's high-quality PPE range – has become the "Official Face Mask Supplier" of the Hong Kong, China Delegation travelling to the upcoming 2020 Tokyo Olympics Games (Tokyo 2020), under a partnership with the Sports Federation & Olympic Committee of Hong Kong, China (SF&OC).

As Official Face Mask Supplier, MainettiCare will provide 100% Made in Hong Kong high-performance HK96 Nanofiber Filter 3D Face Masks (HK96(TM)) and the MainettiCare Disposable Masks (ASTM Level 3) to the travelling Hong Kong, China Delegation. This essential PPE will safeguard athletes and officials from Covid-19 while providing maximum performance and comfort.

MainettiCare's HK96(TM) masks offer better breathability and maintains more than 98% Bacterial Filtration Efficiency (BFE), Particle Filtration Efficiency (PFE) and Viral Filtration Efficiency (VFE) even after 96 hours of continuous use, as tested by Intertek, an independent international laboratory. The ergonomically designed masks also feature adjustable earloops for a tight fit while ensuring comfort during workouts.

Mr. Paul Tai, Regional Director of the Far East & Global Head of MainettiCare, said, "We are incredibly honored that MainettiCare has been selected as the "Official Face Mask Supplier" to the Hong Kong, China Olympic Delegation to Tokyo 2020. With sustainability being a key focus of the Tokyo 2020 Olympics Games, the ability of the HK96(TM) mask to be used for up to 96 hours is an important feature, and also highlights Mainetti's own commitment to sustainability as part of its 60th Anniversary celebrations.

"We look forward to the many proud moments that our local Olympians and Paralympians are sure to provide. We wish them every success as they go for gold in Japan."

About Mainetti
For sixty years, Mainetti has been a trusted partner to the world's most respected and well-known retail and apparel brands. Our 6,000 employees in 90 locations on 6 continents come to work every day with a mission to deliver innovative and sustainable solutions for our customers.

As the largest hanger company in the world, the name Mainetti is synonymous with superior quality and exceptional service. Mainetti pioneered garment hanger reuse and recycling, introducing sustainability practices that continue to lead the industry.

Mainetti's diversified portfolio includes Packaging, Branding, Supply Chain, and Intelligent (RFID) Solutions, and in 2020, we introduced a line of Health and Safety products that help customers in their efforts to mitigate Covid-19 risks. Our holistic supply chain process uses innovative materials to create products with less energy and more renewable sources every year.

Mainetti is a proud Member of the Ellen MacArthur Foundation, working with the world's leading and most influential organizations to accelerate the global transition to a circular economy. Please visit www.mainetti.com for more information.

For media enquiries, please contact:
Think Alliance Group
Henry Chow / Matthew Schultz
Tel: +852 3481 1161
Email: henry.chow@think-alliance.com / matt.schultz@think-alliance.com

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Malaysia Permission Granted for COVID-19 Test Kit from China for Emergency Use; Homegrown Holista Colltech Receives Initial Order for 15,000 Units for Deployment

KUALA LUMPUR, Jun 18, 2021 – (ACN Newswire) – Amid rising concerns about the threat and economic impact of COVID-19, Holista Colltech Limited has been granted permission for Special access under the Medical Device (Exemption) Order 2016, from the Medical Devices Authority ("MDA") of Malaysia's Ministry of Health ("MOH") to import and distribute for an antigen rapid test kit (RTK-AG) developed and manufactured by Guangdong Hecin Scientific Inc. ("Hecin") of China. With this approval, the Company has secured an initial order for 15,000 units in Malaysia.

Holista Colltech Limited ("Holista"), a natural wellness and health products specialist headquartered in Petaling Jaya and listed on the Australian Securities Exchange ("ASX: HCT"), said the Hecin(TM) 2019-nCOV diagnostic test kits will be used to detect the presence of the SARS-CoV-2 viral antigen from nasal swabs within 15 minutes.

Antigen tests look for the coating or proteins of the virus while Polymerase Chain Reaction ("PCR") tests detect its nucleic acid, or genetic material (also known as RNA). The former can deliver results within minutes and generally cost less; the latter, while more accurate, can take up to several days and are generally more expensive.

The 15,000 units will be shipped by the end of this month to Klinik Mutiara, part of Amegajaya Sdn Bhd, a medical consultancy that works closely with MOH and related organizations. The maiden order secured by Holista's wholly owned Holista Biotech Sdn. Bhd. is worth approximately A$95,000 (US$73,000). The kits will be used by registered professionals at Klinik Mutiara for screening purposes.

MOH's Medical Devices Authority ("MDA") has granted Holista permission to import and distribute up to 45,000 units of the Hecin antigen test kit for emergency use within three months from the date of approval on 14th June 2021.

The clinical performance of Hecin RTK-Antigen test kit against PCR Comparator method using nasopharyngeal swabs specimens has obtained a sensitivity of 96.23% and specificity 99.07%. The trial was carried out in Daye City Center for Disease Control and Prevention within China. The results serve as the basis for obtaining the CE mark in Europe. The MDA also conducted its own clinical trials in Malaysia prior to this approval.

The MDA has also granted Holista similar import and distribution approval for Hecin Antibody Test kit which can test human serum, plasma or whole blood for levels of antibodies to assess immunity after vaccination.

Holista has rights to distribute the Hecin COVID-19 test kits in Brunei, Thailand, Indonesia, Philippines, Taiwan, Vietnam, Cambodia, Laos, Myanmar, Singapore and the United Kingdom.

The channel distribution will be handled by Holista's long-time partner, Zuellig Pharma.

Holista will build upon the approvals and commercial arrangements for these test kits to extend distribution rights and partnerships worldwide for pandemic-related infection control, testing and related healthcare solutions.

"The pandemic has impacted Malaysia severely with rising infections, deaths and prolonged movement controls which have disrupted business, education, social interaction and many other activities. Rapid testing is the key to controlling the spread of infection and revive economic activity with confidence," said Holista's CEO, Dato' Dr Rajen Manicka.

"An infected person can spread the virus for several days without showing symptoms. To counter this, regular antigen RTK testing can curb infections control in a very affordable manner. High frequency mass testing has been hugely successful in curbing infections in China, South Korea, Slovakia, Switzerland and the United Kingdom. We are glad that they are being introduced in Malaysia," he said.

"The Slovakia approach of testing brought infections down by more than 50%. Its success has been reported by British Medical Journal, The Lancet, Science and Scientific American earlier this year," Dato' Dr Rajen added.

Holista has also developed a mobile application that allows efficient tracking and tracing based on the 'Traffic Light' model that has been successfully deployed by the National Health Service in the United Kingdom.

About Holista CollTech Limited

Holista CollTech Ltd ("Holista") is a natural wellness company with the following divisions:
– Infection Control Solutions
– Dietary supplements
– Food Ingredients
– Ovine collagen

Holista has a global collaboration with Global Infection Control Consultants LLC to use Path-Away�, a plant-based solution that is proven to kill a broad spectrum of microbes. The all-natural alcohol-free active ingredient is used in Holista's range of sanitising products under the NatShield� brand.

Listed on the Australian Securities Exchange ("ASX"), Holista researches, develops, manufactures and markets health style products. Holista's suite of ingredients includes low GI baked products, reduced-sodium salts, low-fat fried foods and low-calorie sugar without compromising taste, odour and mouthfeel. Holista also produces sheep (ovine) collagen using patented extraction methods. For more information on Holista, please visit https://www.holistaco.com/

Media Contact:
WeR1 Consultants Pte Ltd
E: holista@wer1.net
M: +65 6721 7161

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Cofttek Announces Mass-Production and Supply of Urolithin A & B

LUOHE CITY, China, Jun 15, 2021 – (ACN Newswire) – Cofttek Holding Limited, a Chinese pharmaceutical manufacturer, will mass-produce and supply the latest Urolithin A & B product to dietary supplement companies from June 2021. With 5 years of research into ellagitannins, the source of urolithins, Cofttek is the only pharmaceutical facility in the world able to mass-produce Urolithin A & B.

Following 5 years of research, Cofttek has become the only facility in the world able to mass-produce Urolithin A & B. (Cofttek.com)

Urolithin A possesses anti-inflammatory, anti-oxidant, anti-cancer, hypoglycemic and other biological properties. Urolithin A can improve the quality and function of mitochondria, and increase the strength and endurance of ageing muscles. Urolithin B has anti-inflammatory and antioxidant properties and is also a regulator of skeletal muscle mass.

Studies have shown Urolithin A & B in combination can be used in treating intervertebral disc degeneration (IDD), Alzheimer's and dementia-related disorders, and other diseases. After 5 years of technical research, Cofttek's production capacity of Urolithin A & B now exceeds 2000 kg/month – the only biochemical firm worldwide to have achieved mass production.

About Urolithin

Urolithins are secondary metabolites of ellagic acid derived from ellagitannins. Ellagitannins are converted by the human gut microflora into ellagic acid which is further transformed into urolithins A, urolithin B, urolithin C and urolithin D in the large intestines. Know more at https://www.cofttek.com/products/urolithin/

About Cofttek

Cofttek Holding Limited, founded in 2008, is a high-tech pharmaceutical biochemical enterprise, integrating production, R&D and sales. It is located in Luohe Chemical Industry Park, Luohe City, Henan Province, and is committed to the research and development of advanced pharmaceuticals, providing innovative products and high-quality services for the pharmaceutical industry.

Media Contact:
Dr. Zeng, Cofttek Holding Limited
E: info@cofttek.com, T: +86 1390 2465871
Website: https://www.cofttek.com

SOURCE: Cofttek Holding Limited

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

EC Healthcare Acquires Pet Industry Business, Allowing Clientele and Business Synergies, To Consolidate and Corporatize Pet Industry

HONG KONG, Jun 15, 2021 – (ACN Newswire) – EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group enters the pet industry and will acquire 51% equity interests in King Equity, Eternal Harvest, HKVIC and Crown Leader (the "Target Companies") from Dr. Tiong and Dr. Tan for a total consideration of HK$66.00 million in cash. The Target Companies are principally engaged in the provision of veterinary services in Hong Kong and operate two veterinary hospitals and two veterinary imaging centres in Hong Kong with 14 registered veterinary surgeons, each Target Company operates a veterinary hospital/veterinary imaging centre. According to the unaudited financial information for the year ended 31 March 2021, the profit after tax and net assets of the Target Companies amounted to HK$21.87 million and HK$30.28 million respectively. Upon completion of the acquisitions, the financial results of the Target Companies will be consolidated into the consolidated financial statements of the Group.

Each of Dr. Tiong and Dr. Tan guarantees to the Group that the aggregate guaranteed accumulated net profit of King Equity for the seven financial years ending 31 March 2028 should be no less than HK$121.40 million; Dr. Tiong guarantees to the Group that the accumulated aggregate guaranteed net profit of Eternal Harvest, HKVIC and Crown Leader for the five financial years ending 31 March 2026 should be no less than HK$49.69 million.

Mr. Levin Lee, Executive Director and Chief Finance Officer of EC Healthcare said, "In view of the massive demand for veterinary services in Hong Kong, while the market is still fragmented and lack of management efficiency. The existing issues include the lack of effective performance management, diversified traffic sources, big data analysis of customer behavior, and systematic customer services. EC Healthcare targets to leverage its proven outstanding capability in consolidating the Hong Kong medical market, the Group's brand services, the information technology platform and the efficient corporatization capabilities to empower the fragmented and inefficient pet service assets, and further reform and upgrade the pet service market."

EC Healthcare is always committed to building up an enclosed eco-system focusing on satisfaction of the Group's clients. The Group is optimistic about the prospect of the Target Companies and considers it will diversify the Group's business portfolio, enhance the loyalty and stickiness of the Group's existing customers. This new business will provide a new source of income to the Group and allow synergies to be achieved between the business of the Target Companies and that of the Group, thereby further consolidating the Group's industry leadership as an integrated medical and healthcare group.

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories and a professional hair care center HAIR FOREST.

*According to an independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

For further information, please contact:
iPR Ogilvy Limited
Callis Lau / Lorraine Luk / Shana Li / Ada Chew
Tel: (852) 2136 6952 / 2169 0467 / 3920 7649 / 3920 7650
Fax: (852) 3170 6606
Email: ech@iprogilvy.com

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com